Related Experiment Video
Updated: Jul 16, 2026
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis
Shannon L Gibson1, Zhefu Ma, Leslie M Shaw
1Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Abstract:
The insulin receptor substrate (IRS) proteins are cytoplasmic docking proteins that function as essential signaling intermediates downstream of activated cell surface receptors, many of which have been implicated in breast cancer. The IRS proteins do not contain intrinsic kinase activity but rather function by organizing signaling complexes to initiate intracellular signaling cascades. IRS-1 and IRS-2 are expressed in normal mammary epithelial cells and in breast carcinoma cells, where they have been implicated in mediating signals to promote tumor cell survival, growth and motility. Although IRS-1 and IRS-2 are homologous, recent studies have revealed distinct functions for these adaptor proteins in regulating breast cancer progression. Specifically, IRS-2 is a positive regulator of metastasis, whereas IRS-1 may be a suppressor of metastasis. The observation that IRS-1 is inactivated in metastatic mammary tumors raises the possibility that IRS activity, rather than expression, may be a novel predictive indicator of metastasis. Understanding how the IRS proteins function in tumor progression is essential for future efforts aimed at developing approaches to target IRS-1 and IRS-2 in a diagnostic or therapeutic manner for the benefit of breast cancer patients.
Insights
Insulin receptor substrate (IRS) proteins are key in breast cancer signaling. IRS-2 promotes metastasis, while IRS-1 may suppress it, offering potential diagnostic and therapeutic targets.
Area of Science:
- Molecular biology
- Cancer research
- Cell signaling
Background:
- Insulin receptor substrate (IRS) proteins are crucial cytoplasmic docking proteins.
- They act as signaling intermediates downstream of activated cell surface receptors, often implicated in breast cancer.
- IRS proteins organize signaling complexes to initiate intracellular cascades, lacking intrinsic kinase activity.
Purpose of the Study:
- To elucidate the distinct roles of IRS-1 and IRS-2 in breast cancer progression.
- To investigate the potential of IRS activity as a predictive indicator of metastasis.
- To understand IRS protein function for developing targeted diagnostic or therapeutic strategies.
Main Methods:
- Analysis of IRS-1 and IRS-2 expression and activity in mammary epithelial and carcinoma cells.
- Comparative studies on the functional roles of IRS-1 and IRS-2 in tumor cell survival, growth, motility, and metastasis.
- Investigation of IRS-1 inactivation in metastatic mammary tumors.
Main Results:
- IRS-1 and IRS-2 are expressed in both normal mammary epithelial and breast carcinoma cells.
- IRS-2 acts as a positive regulator of metastasis, while IRS-1 may function as a suppressor.
- IRS-1 inactivation is observed in metastatic mammary tumors, suggesting activity as a metastasis indicator.
Conclusions:
- Distinct functions of IRS-1 and IRS-2 significantly impact breast cancer progression and metastasis.
- IRS activity, not just expression, may serve as a novel predictive marker for metastasis.
- Targeting IRS-1 and IRS-2 holds promise for future breast cancer diagnostics and therapeutics.
